Our platforms are catalyzing drug discoveryfor all major diseases

ELVIS^™&ROSALYND^™

We are therapeutic area agnostic, and are currently applying our platforms to novel hit discovery, hit-to-lead, and lead optimization campaigns in the following disease areas.